Surfing the MASH Tsunami

Send us Fan Mail SurfingNASH's Digital ILC coverage ends with three late-breaking drug presentations, a discussion of EASL's COVID efforts, and insights on patient management. Professor Joern Schattenberg joins the Surfers to discuss the last day of Digital ILC. Donna Cryer and Roger Green praise the work EASL has done pulling together data and analysis on how #liverdisease affects #COVI...

Send us Fan Mail Drugs in development and diagnostics show promise but healthcare has far to go in identifying and treating patients in need. Professor Vlad Ratziu joins the Surfers to discuss Day Two's presentation. The day produced exciting presentations about drugs in development and suggestive findings of the role non-invasive tests and markers can play in predicting patient success. At t...

Send us Fan Mail One day into the first-ever digital major conference, the Surfers review six presentations and one interactive session. A lot was learned, much of which did not fit into neat categories. The Surfers and guest Naim Alkhouri reviewed six presentations and one interactive session formally (points from other presentations crept in once or twice). Like the day itself, the group came to...

Send us Fan Mail The group discusses the plusses and minuses of digital conferences compared to traditional in-person events. Digital ILC starts Thursday, August 27. Donna Cryer, who oversaw the first Digital International NASH Day this year, and Stephen Harrison, who co-chairs NASH-TAG, discuss the factors that organizers consider when deciding whether to go digital and planning how to make it wo...

Send us Fan Mail The second part of the "What NASH patients want" series focuses on the future of healthcare apps and the role government agencies such as FDA, NIH, CMS, and EMEA can play in providing hope or increasing concern and anxiety based on their decisions and the consistency of their messages. In discussing apps, Fatty Liver Foundation President Wayne Eskridge, a trained electri...

Send us Fan Mail Patient advocates discuss how doctors and other providers can serve patient needs better Guest surfer Anthony Villiotti, President of NASH kNOWledge, Inc. joins the Surfers. Tony and Surfer Donna Cryer, President & CEO of Global Liver Institute, discuss the way that better delivery of disease information and care can keep patients healthier longer and make them more knowledgea...

Send us Fan Mail Donna Cryer, President & CEO of the Global Liver Institute, and Louise Campbell, Founder of Tawazun Health, become Surfing regulars in an episode focused on the pivotal papers at EASL's Digital ILC meeting August 27-29. The group discusses the section addressing COVID-19 and liver disease links along with presentations and posters discussing use of FibroScan, AI-aided tes...

Send us Fan Mail The Surfers focus on steps Allied Health Professions and passionate physicians can take to improve lifestyle compliance with #NASH and #NAFLD therapies. The group explores whether the healthcare system can be as effective as companies like Noom and WeightWatchers. This week's Music from the Liver Community: beautiful Oud music from Dr. Naim Alkhouri.

Send us Fan Mail FOCUS: Some of the presentations that will make NASH/NAFLD news next month Transplant hepatologist Naim Alkhouri joins the Surfers in discussing a dozen intriguing paper or session titles listed as part of the scientific program at next month’s Digital International Liver Congress. The discussion touches briefly on SurfingNASH’s plans for expanded Digital ILC coverage and even fea...

Send us Fan Mail NASH is not merely a byproduct of obesity. The role the liver plays in non-liver comorbidities is complex and important. Join the Surfers as they give the liver the respect it’s due. “The ways liver affects outcomes is a very, very complex topic which, for the sake of argument, is sometimes simplified down to obesity…but like our perspective on NASH demonstrates, there's a lo...

Send us Fan Mail FOCUS: Three sets of tools that will improve NASH disease understanding. The Surfers return to diagnostics once more. This time, they explore the utility of novel blood and serum tests, assess the benefits of smaller imaging devices and consider the impact that artificial intelligence and machine learning can have in improving how we diagnose and what we learn from biopsies…one mo...

Send us Fan Mail Decoding the message of Intercept’s Complete Response Letter Former FDA Director Brian Harvey joins the Surfers to discuss what obeticholic acid’s rejection might mean for other NASH medicines in development. Is this the end of accelerated approvals? Does it simply mean we need better drugs? Join the debate

Send us Fan Mail CONSENSUS: the big story will be the regrowth of COVID-19 in the US and its implications. The Surfers discuss different elements of the evolving COVID-19 story — what it feels like to live in an emerging “hotspot” city, new findings on the impact Fatty Liver Disease may have on disease severity, and the commercial implications of all this. #NASH #NAFLD #FattyLiverDisease # COVID #...

Send us Fan Mail What would create greater value for patients and providers? Professor Mary Rinella of Northwestern University and Suneil Hosmane of GenFit join Stephen, Louise, and Roger to explore which of these strategies can do the most to improve patient diagnosis and management. The answer might surprise you.

Send us Fan Mail Surfing the NASH Tsunami celebrates a growing and increasingly important global event for the Fatty Liver community. Global Liver Institute President & CEO Donna Cryer joins the Surfers to discuss the focus, passion and advocacy that have shaped and grown International NASH Day. Learn how IND started and what it represents today. As you listen, envision the role you can play i...

Send us Fan Mail Room for improvement GenFit Head of Global Diagnostics Suneil Hosmane joins the Surfers in exploring the current strengths and drawbacks of Fatty Liver diagnostics. The conversation considers the needs of drug developers, clinicians and patients, and highlights opportunities for improving diagnostic options.

Send us Fan Mail Reviewing press releases reporting preliminary findings from six recently announced Phase 2 trials Stephen Harrison leads the Surfers, with guest Louise Campbell, through an examination of six Phase 2 clinical trials that put forth press releases during the last three months. In all, the discussion created an air of optimism based on better clinical outcomes than we have seen with...

Send us Fan Mail Exploring the controversy over the name(s) to use when describing Fatty Liver disease(s) Professor Quentin Anstee joins the Surfers for a thoughtful consideration of the factors that should drive the decision on what name(s) to use for different Fatty Liver diseases. The group considers a range of issues from our level of scientific knowledge to the semiotics of naming to how pati...

Send us Fan Mail Clinical trial results that are changing how we look at NASH Stephen Harrison leads a review of two recent Phase 3 data statements: the outcome of GenFit’s RESOLVE-IT trial and Madrigal Pharmaceuticals’ recent press release on the extension of its MAESTRO Phase 3 NASH trial. Listen to a thoughtful, far-reaching sometimes funny conversation as the group explores WILD TIMES IN NASH-...

Send us Fan Mail Three possible scenarios for development of the NASH market. Roger Green presents three possible directions for the NASH market over the next 5-10 years and asks our panelists, including our guest, renowned nurse and patient advocate Louise Campbell, to suggest critical market-driving factors. Browse Our NASH and COVID-19 Coverage  https://surfingnash.com/covid-19/

Send us Fan Mail Critical considerations for companies developing NASH drugs Peter Traber focuses on ways COVID-19 can affect drug development and broader corporate strategies while our panelists weigh in on implications for clinical researchers, investors and forecasters in our third episode: C-SUITE COVID-19 CHALLENGES. Browse Our NASH and COVID-19 Coverage  https://surfingnash.com/covid-19/

Send us Fan Mail What investors want to know about NASH development during the pandemic. Yasmeen Rahimi poses five questions NASH investors ask her about the impact of COVID-19 on NASH clinical and commercial development and our panelists provide answers in our second episode, FIVE $IMPLE PIECES: What investors want to know about NASH development during the pandemic.

Send us Fan Mail Navigating NAFLD/NASH clinical trials through the pandemic Dr. Stephen Harrison discusses several ways the pandemic is affecting planning and execution of clinical trials and our panelists discuss implications for investors, C-suite executives and forecasters in our first episode, COVID CHAOS: Navigating NAFLD/NASH clinical trials through the pandemic. Browse Our NASH and COVID-19...